Yüklüyor......
Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
Exploring resistance mechanisms in patients with EGFR-mutant non-small-cell lung cancer (NSCLC) upon disease progression on EGFR tyrosine kinase inhibitors (TKIs) has been an area of great interest as it may lead to effective next-line treatment strategies. Here we report a case of emergent MET ampl...
Kaydedildi:
| Yayımlandı: | Lung Cancer (Auckl) |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6419586/ https://ncbi.nlm.nih.gov/pubmed/30881166 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S190403 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|